Looking for an insulin pill? Use the BRET methodology!

T Issad1, N Boute, S Boubekeur

  • 1Department of Cell Biology, Institut Cochin, CNRS-UMR 8104, INSERM U567, Université Paris V, Paris, France. issad@cochin.inserm.fr

Insights

Bioluminescence Resonance Energy Transfer (BRET) can monitor insulin receptor activity and interactions with phosphatases. This method aids in discovering drugs for insulin resistance and deficiency.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Insulin receptor tyrosine-kinase activity is crucial for its biological effects.
  • Autophosphorylation and dephosphorylation regulate insulin receptor activity.
  • Developing agents to modulate insulin receptor activity is vital for treating insulin resistance and deficiency.

Purpose of the Study:

  • To investigate the utility of Bioluminescence Resonance Energy Transfer (BRET) for studying insulin receptor activation and its interactions.
  • To establish BRET as a high-throughput screening method for identifying novel therapeutic agents.

Main Methods:

  • Utilized BRET by fusing insulin receptor subunits to Renilla luciferase and Yellow Fluorescent Protein (YFP).
  • Monitored conformational changes and activation states of the insulin receptor in response to ligands.
  • Assessed BRET signal changes to detect interactions between the insulin receptor and protein tyrosine-phosphatase 1B (PTP1B).

Main Results:

  • Demonstrated that BRET can detect insulin receptor activation by various ligands through conformational changes.
  • Showed that BRET can monitor real-time interactions between the insulin receptor and PTP1B.
  • Validated BRET as a tool for rapid analysis of insulin receptor activity.

Conclusions:

  • BRET is an effective methodology for studying insulin receptor activation and dephosphorylation dynamics.
  • BRET enables high-throughput screening for agonists with insulin-like properties.
  • BRET can identify inhibitors of insulin receptor-PTP1B interaction, offering therapeutic potential.

Related Concept Videos

Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...